WecLac® Individual Clinical Strains-Wecare Probiotics

Home
Products
Products

We are leaders in microbiome research, with a focus on probiotic strains, starter cultures, and the influence of beneficial microbial communities on diverse hosts, including humans, animals, and plants.
News
News

We actively participate in international probiotic industry seminars and conferences, sharing our research results and industry insights with leading experts and peers around the world.
- Company News
- Industry Insight
About Us
About Us

We are leaders in microbiome research, with a focus on probiotic strains, starter cultures, and the influence of beneficial microbial communities on diverse hosts, including humans, animals, and plants.
Founder
Founder

We actively participate in international probiotic industry seminars and conferences, sharing our research results and industry insights with leading experts and peers around the world.
- Dr. Frank Fang
Contact Us
Contact Us

We welcome the opportunity to connect with you, share more insights, explore potential partnerships, and work together to drive innovation and growth in the probiotic industry.
- Contact Us
- Join Us

English Français Español Русский

Home > Products > WecLac^® Individual Clinical Strains > Lacticaseibacillus rhamnosus

Lacticaseibacillus rhamnosusLRa05

Potency

600B CFU/g

Source of Strain

Healthy infant intestines

Deposit Number

PTA-126815(ATCC) No.24377(CGMCC)
DSM34693(DSMZ)

Functions

Gastrointestinal Health
Metabolic Health
Emotional Health
Maternal & Child Health
Immune Health
Oral Health

References

[1]Sun M , Wu T , Zhang G , Liu R , Sui W , Zhang M , Geng J , Yin J , Zhang M . Lactobacillus rhamnosus LRa05 improves lipid accumulation in mice fed with a high fat diet via regulating the intestinal microbiota, reducing glucose content and promoting liver carbohydrate metabolism. Food Funct. 2020 Nov 18;11(11):9514-9525. doi: 10.1039/d0fo01720e. PMID: 33063800.

[2]Wu T, Zhang Y, Li W, Zhao Y, Long H, Muhindo EM, Liu R, Sui W, Li Q, Zhang M. Lactobacillus rhamnosus LRa05 Ameliorate Hyperglycemia through a Regulating Glucagon-Mediated Signaling Pathway and Gut Microbiota in Type 2 Diabetic Mice. J Agric Food Chem. 2021 Aug 11;69(31):8797-8806. doi: 10.1021/acs.jafc.1c02925. Epub 2021 Aug 2. PMID: 34340304.

[3]Zhao TS, Xie LW, Cai S, Xu JY, Zhou H, Tang LF, Yang C, Fang S, Li M, Tian Y. Dysbiosis of Gut Microbiota Is Associated With the Progression of Radiation-Induced Intestinal Injury and Is Alleviated by Oral Compound Probiotics in Mouse Model. Front Cell Infect Microbiol. 2021 Oct 25;11:717636. doi: 10.3389/fcimb.2021.717636. PMID: 34760714; PMCID: PMC8573182.

[4]Gai Z, Dong Y, Xu F, Zhang J, Yang Y, Wang Y. Changes in the gut microbiota composition of healthy young volunteers after administration of Lacticaseibacillus rhamnosus LRa05: A placebo-controlled study. Front Nutr. 2023 Mar 14;10:1105694. doi: 10.3389/fnut.2023.1105694. PMID: 36998912; PMCID: PMC10043436.

[5]Gai Z, Liao W, Huang Y, Dong Y, Feng H, Han M. Effects of Bifidobacterium BL21 and Lacticaseibacillus LRa05 on gut microbiota in type 2 diabetes mellitus mice. AMB Express. 2023 Sep 16;13(1):97. doi: 10.1186/s13568-023-01603-1. PMID: 37716924; PMCID: PMC10505128.

[6]Dong Y, Han M, Fei T, Liu H, Gai Z. Utilization of diverse oligosaccharides for growth by Bifidobacterium and Lactobacillus species and their in vitro co-cultivation characteristics. Int Microbiol. 2023 Nov 9. doi: 10.1007/s10123-023-00446-x. Epub ahead of print. PMID: 37946011.

[7]Chen T, Shao Y, Zhang Y, Zhao Y, Han M, Gai Z. In vitro and in vivo genome-based safety evaluation of Lacticaseibacillus rhamnosus LRa05. Food Chem Toxicol. 2024 Apr;186:114600. doi: 10.1016/j.fct.2024.114600. Epub 2024 Mar 13. PMID: 38490350.

[8]Gu J, Chen Y, Wang J, Gao Y, Gai Z, Zhao Y, Xu F. Lacticaseibacillus rhamnosus LRa05 alleviated liver injury in mice with alcoholic fatty liver disease by improving intestinal permeability and balancing gut microbiota. Benef Microbes. 2024 Jul 3:1-13. doi: 10.1163/18762891-bja00022. Epub ahead of print. PMID: 38960385.

Introduction

Animal experiments have revealed that LRa05 has significant improvements in high-fat diet mice.

Inhibition of weight, blood lipid levels and lipid accumulation in liver cells and epididymal fat tissue of the high-fat diet group.

Remodeling of the gut microbiota, reducing the abundance of potentially pathogenic Streptococcus.

Lowering of blood and liver glucose levels, and promoting liver carbohydrate and energy metabolism.

LRa05 has the potential to lower blood lipid levels and promote fat metabolism

LRa05 intervention resulted in distinct separation in meta-bolic analysis, with increased levels of certain metabolites and decreased levels of others compared to the high-fat diet group.

Regulate intestinal flora

Regulates the transformation value of spleen lymphocytes, inflammatory factors, and intestinal short-chain fatty acids.

LRa05 inhibits the Streptococcus mutant bacteriostatic zone

Inhibit Pathogens

Use of LRa05 in the preparation of products inhibiting Helicobacter pylori and / or Streptococcus mutans

Use of a LRa05 in the preparation of formulations for improving irritable bowel syndrome

Reduce serum endotoxin and increase levels of anti-inflammatory factors, relieve oxidative stress

LRa05 may have potential as a therapeutic intervention for managing T2DM

LRa05 treatment efectively reduced FBG levels, improved alucose tolerance, decreased insulin levels. reduced insulin resistance, and increased hepatic glycogen levels in T2DM mice.

Weight Management

A probiotic that regulates the level of intestinal hormone GLP-1 and its application

Reduce the levels of serum ALT and AST in obese people

It significantly increases the expression of GLP-1 in small intestinal endocrine cells and the expression of GLP.1 in intestinal tissues of obese people

Reduce weight in obese people

Regulates the transformation value of spleen lymphocytes, inflammatory factors, and intestinal short-chain fatty acids in mice

Diarrhea in children is a digestive tract syndrome caused by multiple pathogens and factors, which is characterized by increased stool frequency and changes in stool consistency. lt is a commonly and frequently occurring disease in children and is easy to cause malnutrition and restricted growth and development in children. The present study showed that when compared with the children in control group, the use of ready to eat probiotic powder (LRa05)for one week can significantly improve the therapeutic efficacy of children with diarrhea, reduce the frequency of stools, improve the stool consistency and observe no obvious adverse reactions which indicating its safety and reliability.

Subjects

Dosage:Lactobacillus rhamnosus LRa05, 5 x 10⁹ CFU/ sachet, 2g/sachet

Effect of probiotic intervention on daily stool consistency

The total Bristol stool consistent score of daily stool of children in both groups decreased significantly with the extension of treatment time. There were also significant diferences in the total Bristol stool consistent score of daily stool between two groups, and the children in intervention group was significantly lower than that of children the control group.

Bristol stool chart

Effect of probiotic intervention on the total Bristol consistency score of daily stool of children between the two groups

Effect of probiotic intervention on the average Bristol consistency score of daily stool of children

This study showed that with the extension of treatment time, the average Bristol stool consistent score of daily stool of children in both groups decreased significantly. The Bristol stool consistency score of daily stool between two groups, that of children in intervention group was significantly lower than that of children the control group. There was also an interaction between treatment time and intervention mode.

Effect of probiotic intervention on daily stool frequency

With the extension of treatment time, the number of daily defecation decreased significantly in both groups. There was also a significant difference in the frequency of stools between intervention group and control group and the frequency of stools in the intervention group was signifi-cantly less than those of children in the control group. At the same time, there was an interaction between treat-ment time and intervention mode.